Teva wins chemotherapy drug patent ruling

A US court in New Jersey has ruled in favor of Teva Pharmaceutical Industries Ltd. in a chemotherapy drug patent case.

Teva has announced that the US District Court for the District of New Jersey has granted summary judgment in Teva’s favour, ruling that its chemotherapy drug does non-infringe Eloxatin patents held by Sanofi-Aventis. Teva expects that its new chemotherapy medication drug application will receive final approval shortly.



Categories: drugs, infringement, Intellectual Property, Israel Related, pharmaceuticals, pharmaceuticals and Biotechnology, Teva, US

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: